News Releases

August 6, 2019
Neon Therapeutics Reports Second Quarter 2019 Financial Results
Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society meeting Announces U.S. Food & Drug Administration ( FDA ) clearance of Neon’s Investigational New Drug
Additional Formats
July 15, 2019
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal neoantigen-based therapy in the metastatic cancer setting Demonstrated prolonged and consistent
Additional Formats
June 3, 2019
Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Jefferies 2019 Healthcare Conference
Additional Formats
Displaying 1 - 10 of 16